Once the operational figures for the BIOL's 4th quarter are announced, investors will compare this years 4th quarter to the 4th quarter in 2011 and they will jump onto the stock forcing much higher share pricing. Now is the time to buy BIOL before the greater investment community becomes aware of what is happening here. For the moment, these shares are flying well under the radar. Although there was profit taking at the end of today's trading session, I see the shares of BIOL moving smartly forward in the days ahead in anticipation of vastly improved operational performance. I've never seen an investor that does not like a signficant jump in revenue and earnings especially when that trend is very like to continue through 2013 and into 2014.
Cheers and good investing,
Sentiment: Strong Buy
this news pump did not work today?
what was this news?lol
BIOLASE Recognized With "Best AEEDC Dubai Booth Activities Award" at Recent UAE Dental Conference & Arab Dental Exhibition
Press Release: BIOLASE, Inc. – 5 hours ago
Symbol Price Change
BIOL 3.717 -0.14
IRVINE, CA--(Marketwire - Feb 12, 2013) - BIOLASE, Inc. ( NASDAQ : BIOL ), the world's leading manufacturer and distributor of dental lasers, announced today that the Company was recognized with the "Best AEEDC Dubai Booth Activities Award" for the recent UAE International Dental Conference & Arab Dental Exhibition (AEEDC Dubai) held from February 5 - 7, 2013, in Dubai, United Arab Emirates.
Federico Pignatelli, Chairman and Chief Executive Officer, commented, "I am very pleased to see that our WaterLase and EPIC diode technology is so attractive that we had the busiest booth at the AEEDC, more so than any other company including such prestigious companies as Sirona Dental Systems, Inc. ( NASDAQ : SIRO ), The Procter & Gamble, Co. ( NYSE : PG ), and Colgate-Palmolive Co. ( NYSE : CL ). The high level of traffic at our booth underscores the exceptional interest that the global dental community is developing in lasers, where we are the undisputed global leader. We plan to continue to invest in our marketing efforts and conference attendance during the 2013 first quarter in order to build a solid foundation for the rest of the year."
AEEDC Dubai is held under the patronage of His Highness Sheikh Hamdan Bin Rashid Al Maktoum, Deputy Ruler of Dubai, Minister of Finance, and President of the Dubai Health Authority, in co-operation with the Dubai Health Authority. It is the pioneering and largest dental event in the Middle East and North Africa (MENA) region and provides a platform for dental professionals and industry experts from the MENA region and other parts of the world to update their knowledge, network, interact, and generate business partnerships. Organizers estimate that this year's exhibition had over 1,000 dental equipment suppliers from 70 countries and over 28,000 attendees.
"We are delighted to receive this recognition and I would like to thank Dr. Nasser Al Malik, Conference Chairman, for presenting this award to BIOLASE," said Bill Brown, Vice President of Sales and Marketing. "AEEDC Dubai is the foremost event in the MENA region and to be recognized as the company with the best booth activities is very rewarding. This marks our third time exhibiting at AEEDC Dubai and it has been great to observe the tremendous growth in the interest of dental lasers in the region during that period."
About BIOLASE, Inc.
BIOLASE, Inc. is a biomedical company that develops, manufactures and markets dental lasers and also distributes and markets dental imaging equipment; products that are focused on technologies that advance the practice of dentistry and medicine. The Company's laser products incorporate approximately 290 patented and patent-pending technologies designed to provide biological treatment and clinically superior performance with less pain and faster recovery times. Its imaging products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment and CAD/CAM systems. BIOLASE has sold more than 21,000 lasers.
Other products under development address ophthalmology and other medical and consumer markets.
For updates and information on W
Sentiment: Strong Sell
Last year they annonced 4Q11 results on March 8th. Volume up 36% YOY to $13.2M. The closing price on March 1st was $2.68. The closing price was on April 1st was $2.72.
This yeart they preannounced $18M in volume which is up 36% YOY from 4Q11. And the retiredtechie thinks the price will double?
The problem last year was they LOST $4.5M in FY11. They look to lose a little more in FY12. why would the company DOUBLE in price when they have ~$5M less cash now than they did last year. Yahoo reports Biolase's book value is $0.33 and their enterprise value is $1.43. Both will likely fall AGAIN after 4Q12 announcements.
PPut the Kool Aid now and step away from the glass. IMHO, one should use this temporary spike to sell to the true beleivers that can't add.
Sentiment: Strong Sell
DaVinci Imaging™ D3D™ CBCT System: ....Imaging sales stink so far at Biolase and It will be Interesting to see how much it contributed to revenues next?
WaterLase sytems sales comprised approximately 67.2% of net revenues for the third quarter of 2012, compared to 62.9% for the prior year quarter. The majority of these WaterLase revenues in both quarters were from the sales of the company’s flagship WaterLase iPlus all-tissue laser systems.
Diode laser system sales comprised approximately 6.5% of net revenues for the third quarter of 2012 compared to 16.6% for the prior year quarter. Diode sales were impacted in the third quarter of 2012 pending regulatory clearance of the new EPIC 10 diode laser system. BIOLASE received the CE Mark for the EPIC 10 in the final days of September 2012, and received notice of its regulatory clearance from the FDA on October 1, 2012. As a result, the Company expects that diode laser system sales will increase significantly beginning with the fourth quarter of 2012.
Imaging revenues totaled approximately $675,000, or 4.9% of net revenue, during the third quarter of 2012 as compared to $100,000, or 0.7% of net revenue, for the prior year period, an increase of 575%.
and let us look forward to this number:
Operating expenses in this year third quarter was $6.7 million, or 48.4% of net sales, as compared to $6.3 million, or 47.9% of net sales, in the third quarter of 2011. The increased sales in marketing expense and engineering in development cost as we continue to invest in our new product development were offset in part by lower general and administrative expenses in the 2012 quarter. These increased cost reflect the Company’s continued investment in growing its core business.
If cash is getting depleted than Interest expense should also rise as Management will forced tap credit line for more cash???????????????????
Turning to the balance sheet as of September 30, 2012, we had approximately $6.2 million in working capital. Cash and cash equivalents and restricted cash totaled approximately $1.3 million compared to $1.7 million at June 30, 2012, and $3.3 million at December 31, 2011.
Accounts receivable totaled $10.3 million compared to $9.6 million at June 30, 2012, and $8.9 million at December 31, 2011. Stockholders’ equity was $10.3 million at September 30, 2012. In addition, the Company had two revolving lines of credit totaling $8 million, with $5.1 million of available borrowings, in excess of the $2.2 million outstanding, at September 30, 2012.
BIOL has made great progress over the last 12 months. They have restructured sales to better fit their business and introduced new products to the market. The stock market is forward looking and as such will revalue the shares higher as their sales growth gets noticed. Also, when they start generating a profit and get a P/E, no entity will be able to play games with the stock price. Thankfully BIOL has very few shares outstanding and a capitalization about equal to its yearly sales run rate. At the present growth rate, it won't take much to get the share price up significantly. I am looking forward to a very good year in 2013. They are just getting started with their new sales force. Let's compare notes at the end of this year. I think you will be quite surprised. ;-)
BIOL has not said/guided that they will be making a profit in Q4-12. They only guided that they would be cash flow positive. A profit in Q4-12 would be a pleasant surprise. I think they are well on their way toward profitability with the sales growth they are having. The new products have only recently been introduced and the formation of the new direct sales force has not yet been completed (soon to be complete). The new sales people need a little time to get trained and get comfortable in their new jobs before they can "fire on all cylinders" so to speak. I am looking forward to continued good sales growth through this year. I think this is a good long term investment. Good Luck.
I see glut of Dental Offices in California and they are now doing cut throat business and margins are shrinking, how can they afford to deploy expensive dental laser machines?
With obama care coming into effect next in USA will also have very negative impact on Insurance billing claims and payments
Growth will come to screeching halt again in 2nd half of 2013
Imaging competition is brutal and will get more brutal going forward............
Good luck all
Just few DD brain spin roars form crazy LION
Economics Predictions; Deep recession unfolds in 2nd quarter again and massive lay off in Tech industry are going to unfold...............
MASSIVE CIVIL UNREST is forgone conclusion in USA 2014
"DEPRESSION CYCLE picks up steam in 2nd half of 2013
If you read my above posting, I did not mention that Q4/2012 would result in a profitabable status for BIOL. What I did say was that "bottom line" comparisons to last year in the same quarter will catch investors eyes. Its all about direction and BIOL as you seem to also allude is heading quickly in the right direction. That will be good for the share price. For all practical purposes, I believe you and I are on the same page as we view the forward operational performance of BIOL. It should prove to be a very good investment from current share price levels.
Cheers and good investing,
Sentiment: Strong Buy
Even with a 20%+ pop this thing didn't bring in much volume. I'd stay away from low volume, small cap stocks. It took me over 4 months to get my $ out of this one with a gain. Too easily manipulated.